Duke University

Christopher David Lascola

Philip Floyd Hughes

Daniel T Laskowitz

Timothy Haystead

Jesse Keiser Fitzpatrick

Provided herein according to some embodiments is a compound of Formula (I): [Formula], or a pharmaceutically acceptable salt or prodrug thereof. Compositions comprising the compound, and uses thereof for inhibiting the activity of quinone reductase-2, as well as in methods of treatment, are also provided.

Quinone reductase 2 inhibitor compounds and uses thereof

A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L.

Ascorbate formulations and methods of use as contrast agents

Provided herein are magnetic resonance imaging (MRI) contrast agents comprising a compound having a structure represented by: Y&#x2014;X&#x2014;Z, wherein, X is: Fe(III) or Mn(II), and Y and Z are each independently selected from pyrophosphate and bisphosphonate (e.g., 1-hydroxybisphosphonate), or a pharmaceutically acceptable hydrate and/or salt thereof. Methods of use of the MRI contrast agent are also provided.

Metal complexes with bisphophonate or pyrophosphate useful as imaging agents

Ascorbate or a pharmaceutically acceptable salt thereof is described for use in carrying out a method, or for the preparation of a medicament for carrying out a method, of enhancing a magnetic resonance imaging (MRI) image of a body or body region such as an organ or organ region in a subject. The method is carried out by parenterally administering ascorbate or a pharmaceutically acceptable salt thereof to the subject in an MRI image-enhancing amount; and then generating, by MRI of the subject, an image of the body or body region. The ascorbate or pharmaceutically acceptable salt thereof enhances the MRI image.

Contrast agents for magnetic resonance imaging

Provided herein is a compound useful as a magnetic resonance imaging (MRI) contrast agent and a therapeutic agent, said compound having a structure represented by: Y&#x2014;X&#x2014;Z wherein, X is Mn(II), and Y and Z are each independently a bisphosphonate coupled to one or more therapeutic agents. Methods of use of the compound for MRI imaging and treatment for cancer or a microbial infection are also provided.

Manganese complexes with substituted bisphosphonates useful as imaging and therapeutic agents

Described herein are substituted indazoles comprising formula (II) that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. Formula (II) may link to detection moieties such as fluorophores that may allow for selective detection of Hsp90 in a sample. 

Growing community of inventors

Durham, NC, United States of America

Christopher David Lascola